Purpose
The objective of this study was to determine the clinical distribution, in vitro antifungal susceptibility and underlying resistance mechanisms of
Aspergillus fumigatus
(
A. fumigatus
) isolates from the General Hospital of Ningxia Medical University between November 2021 and May 2023.
Methods
Antifungal susceptibility testing was performed using the Sensititre YeastOne YO10, and isolates with high minimal inhibitory concentrations (MICs) were further confirmed using the standard broth microdilution assays established by the Clinical and Laboratory Standards Institute (CLSI) M38-third edition. Whole-Genome Resequencing and RT-qPCR in azole-resistant
A. fumigatus
strains were performed to investigate the underlying resistance mechanisms.
Results
Overall, a total of 276
A. fumigatus
isolates were identified from various clinical departments, showing an increasing trend in the number of isolates over the past 3 years. Two azole-resistant
A. fumigatus
strains (0.72%) were observed, one of which showed overexpression of
cyp51A, cyp51B, cdr1B, MDR1/2, artR, srbA, erg24A
, and
erg4B
, but no
cyp51A
mutation. However, the other strain harbored two alterations in the
cyp51A
sequences (L98H/S297T). Therefore, we first described two azole-resistant clinical
A. fumigatus
strains in Ningxia, China, and reported one azole-resistant strain that has the L98H/S297T mutations in the
cyp51A
gene without any tandem repeat (TR) sequences in the promoter region.
Conclusions
This study emphasizes the importance of enhancing attention and surveillance of azole-resistant
A. fumigatus
, particularly those with non-TR point mutations of
cyp51A
or non-
cyp51A
mutations, in order to gain a better understanding of their prevalence and spread in the region.